research Alopecia Areata: A Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Tofacitinib for the Treatment of Three Immune-Mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Hair Regrowth in a Patient With Central Centrifugal Cicatricial Alopecia After a 2-Month Trial of Baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Baricitinib For Alopecia Areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman
Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
research An Urticarial Drug Eruption Caused by Tofacitinib for Alopecia Universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Trachyonychia Secondary to Pediatric Alopecia Areata Responding to Oral Tofacitinib Therapy: A Case Report and Review of Literature
Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research Therapeutic Response of Alopecia Areata-Associated Nail Changes to Baricitinib
Baricitinib may effectively treat nail changes in alopecia areata.
research Fzd2 Controls Multiple Aspects of Epidermal Development Through Distinct Signaling Mechanisms
Fzd2 is important for skin and hair development through various signaling ways.
research The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research An Open Label Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research The Development of Oral Hairy Leukoplakia During JAK Inhibitor Baricitinib Therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction
Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.